Stock TLX TELIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Market Closed - Australian S.E.
Other stock markets
 02:10:52 2024-06-03 am EDT 		5-day change 1st Jan Change
18.25 AUD +0.55% Intraday chart for Telix Pharmaceuticals Limited +14.85% +81.05%
07:23am Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy MT
04:49am Telix Pharmaceuticals Completes US FDA Regulatory Submission for Kidney Cancer Imaging Agent MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy
MT
Telix Pharmaceuticals Completes US FDA Regulatory Submission for Kidney Cancer Imaging Agent
MT
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
AQ
Telix Pharma Reports Positive Data from Clinical Study of Prostate Cancer Drug; Shares Surge 15%
MT
Commodity, banking stocks help Australian shares snap 3-day slide
RE
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
AQ
Telix Submits NDA for New Prostate Cancer Imaging Agent
AQ
Telix Pharmaceuticals Submits New Drug Application for Prostate Cancer Imaging Agent to US FDA
MT
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent
CI
Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug
MT
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
AQ
Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO
MT
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
AQ
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.
CI
Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP
MT
Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591
AQ
Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50
MT
Telix - Notice of Annual General Meeting 2024
AQ
Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy
MT
Q1 2024 Revenue and Business Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLX Stock
  4. News Telix Pharmaceuticals Limited